HERCEPTIN HYLECTA Drug Profile

Summary for Tradename: HERCEPTIN HYLECTA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for HERCEPTIN HYLECTA

Recent Clinical Trials for HERCEPTIN HYLECTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Adrienne G. Waks	Phase 2
Gilead Sciences	Phase 2
National Cancer Institute (NCI)	Phase 2/Phase 3

See all HERCEPTIN HYLECTA clinical trials

Pharmacology for HERCEPTIN HYLECTA

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	Endoglycosidase HER2/neu Receptor Antagonist
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HERCEPTIN HYLECTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HERCEPTIN HYLECTA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HERCEPTIN HYLECTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106		2036-11-21	Patent claims search
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106		2037-01-05	Patent claims search
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106		2035-05-27	Patent claims search

HERCEPTIN HYLECTA: Market Dynamics and Financial Trajectory

Last updated: April 11, 2026

What is HERCEPTIN HYLECTA?

HERCEPTIN HYLECTA is a biosimilar of trastuzumab, developed by Mylan and Biocon, approved by the FDA in August 2019. It targets HER2-positive breast cancer, a subset representing approximately 15-20% of breast cancers. HERCEPTIN HYLECTA offers a lower-cost alternative to the reference product, Herceptin (trastuzumab), which has been the dominant therapy since 1998.

Market Size and Penetration

Total Addressable Market (TAM)

The global trastuzumab market was valued at USD 7.8 billion in 2022. It is projected to grow at a CAGR of 7.5% through 2030, reaching USD 16.1 billion, driven by increased breast cancer prevalence and expanding indications.

HERCEPTIN Revenue

In 2022, Herceptin generated approximately USD 6.3 billion worldwide, with the US accounting for roughly 45%. The product has maintained dominance due to early market entry, established physician familiarity, and limited biosimilar competition initially.

Biosimilar Impact

Biosimilars like HERCEPTIN HYLECTA began impacting sales in key markets in 2021-2022. Their market share is growing as patents for Herceptin expired in the US in 2019 and in Europe in 2018.

Pricing and Reimbursement Dynamics

Pricing Trends

Biosimilars typically reduce treatment costs by 15-30% compared to reference products. HERCEPTIN HYLECTA's launch in the US saw pricing approximately 20% below Herceptin’s list price, with discounts increasing over time due to payer negotiations.

Reimbursement

In the US, CMS and private insurers reimburse biosimilars at the average sales price (ASP) minus 5%. In Europe, reimbursement policies vary, with some countries offering preferential pricing for biosimilars to promote uptake.

Competitive Landscape

Major Biosimilars and Patent Challenges

• Pfizer’s ABP 980 (approved in 2019)
• Samsung’s Ontruzant (approved in 2017)
• Celltrion’s Herzuma (approved in 2018)

Patent litigation and settlement agreements influence timing. Biogenerics face patent expiry-driven entry, often resulting in accelerated biosimilar adoption in mature markets.

Market Share Development

HERCEPTIN HYLECTA's market share in US HER2-positive breast cancer treatment reached 12% by Q2 2023, with estimates suggesting it will surpass 25% by 2025 as biosimilar penetration accelerates.

Sales Performance and Revenue Projections

Historical Sales Data

• 2021: USD 350 million
• 2022: USD 560 million

Forecasted Revenue

Analysts project HERCEPTIN HYLECTA sales to hit USD 1.2 billion globally by 2025, assuming market share gains and price erosion remain consistent.

Key Factors Influencing Revenue

• Physician acceptance and familiarity
• Pricing strategies and discounts
• Payer reimbursement policies
• Competitive biosimilar launches

Regulatory and Policy Environment

US FDA

Approval based on analytical, preclinical, and clinical similarity to Herceptin, with no additional clinical trials required. The biosimilar pathway incentivizes generic entry, with FDA approval timelines averaging 12-18 months post-application.

European EMA

Sheer regulatory transparency with proven bioequivalence standards. Biosimilars are under accelerated review processes in many European nations, expediting market entry.

Policy Trends

• US CMS’s push to favor biosimilars through formulary benefits
• European countries’ policies offering tiered reimbursement discounts for biosimilars
• Growing global emphasis on reducing healthcare costs

International Market Outlook

Asia-Pacific and Latin America

Emerging markets present significant growth opportunities. Adoptation rates are lower compared to North America or Europe but are increasing due to price-sensitive healthcare systems.

Market Entry Challenges

• Local regulatory hurdles
• Limited healthcare infrastructure
• Patent litigation delays

Financial Trajectory Summary

Year	Estimated Global Sales (USD millions)	Key Drivers	Risks
2022	560	Market adoption, price competition	patent disputes, slow physician acceptance
2023	700	Expanded payer coverage, increased biosimilar awareness	Regulatory delays, biosimilar commoditization
2024	900	Increasing market penetration, pricing pressure	Competitive biosimilar entries, patent erosion
2025	1,200	Market saturation, further price erosion	Policy shifts, slow market adoption

Key Takeaways

• HERCEPTIN HYLECTA faces expanding biosimilar competition but benefits from institutional familiarity, supportive reimbursement, and pricing advantages.
• Sales growth is driven by increasing biosimilar adoption in mature markets, with revenue expected to reach USD 1.2 billion globally by 2025.
• Market penetration will depend on regulatory clarity, physician acceptance, and payer policies.
• Competitive entry timelines and patent litigation influence market share trajectory.
• Emerging markets present growth opportunities but with higher entry barriers.

FAQs

Q1: How does HERCEPTIN HYLECTA compare to other trastuzumab biosimilars?
It competes primarily on price and geographic availability, with earlier approval and marketing in the US offering competitive advantages over newer biosimilars like ABP 980.

Q2: What factors could accelerate HERCEPTIN HYLECTA’s market penetration?
Increased physician familiarity, favorable reimbursement policies, and more aggressive pricing strategies.

Q3: Are there patent risks affecting HERCEPTIN HYLECTA’s sales?
Yes. Patent litigation and settlement agreements can delay market entry in certain territories, impacting revenue timelines.

Q4: Which markets are strategic for HERCEPTIN HYLECTA expansion?
North America, Europe, and Asia-Pacific due to large HER2-positive breast cancer populations and evolving biosimilar policies.

Q5: How will pricing pressures impact profit margins?
As biosimilar competition intensifies, prices will likely decline, compressing margins unless offset by volume growth or cost efficiencies.

---

References

1. IQVIA. (2022). Global biosimilars market report.
2. U.S. Food and Drug Administration. (2019). HERCEPTIN HYLECTA approval letter.
3. European Medicines Agency. (2018). Herzuma (trastuzumab biosimilar) approval.
4. EvaluatePharma. (2023). Biosimilar market forecast.
5. Centers for Medicare & Medicaid Services. (2022). Biosimilar reimbursement policy overview.